CompletedNCT00621777
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolarity
Medication studyAges 18–70United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 70 years.
- Listed locations
- Birmingham and 9 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateFebruary 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 247
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00621777
- Official title
Show the full official title
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Get this study by email
Recruitment & locations
CompletedBirmingham · Bloomington · Boston
6 more locations
- Grand Rapids
- Minneapolis
- Claremont
- Concord
- Manchester
- Nashua
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Varenicline and Placebo.
Who was this study for?
Listed age limits: 18 years to 70 years.
Want to explore more studies?
Explore studiesRelated studies
A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolarity type I, or Schizoaffective Disorder
A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode